JP2010518860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518860A5 JP2010518860A5 JP2009550979A JP2009550979A JP2010518860A5 JP 2010518860 A5 JP2010518860 A5 JP 2010518860A5 JP 2009550979 A JP2009550979 A JP 2009550979A JP 2009550979 A JP2009550979 A JP 2009550979A JP 2010518860 A5 JP2010518860 A5 JP 2010518860A5
- Authority
- JP
- Japan
- Prior art keywords
- minutes
- substrate
- test compound
- lyn kinase
- atp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 239000000758 substrate Substances 0.000 claims 12
- 108091000080 Phosphotransferase Proteins 0.000 claims 7
- 102000020233 phosphotransferase Human genes 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 102000001253 Protein Kinase Human genes 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical group 0.000 claims 4
- 108060006633 protein kinase Proteins 0.000 claims 4
- 230000026731 phosphorylation Effects 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 0 *c1c(*)c(*)c(*C(C(*)=N2)=C(*)N(*)C2=*)c(*)c1* Chemical compound *c1c(*)c(*)c(*C(C(*)=N2)=C(*)N(*)C2=*)c(*)c1* 0.000 description 2
- -1 5,6,7,8-tetrahydronaphthyl Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89063207P | 2007-02-20 | 2007-02-20 | |
| PCT/US2008/054361 WO2008103692A2 (en) | 2007-02-20 | 2008-02-20 | Methods of identifying activators of lyn kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518860A JP2010518860A (ja) | 2010-06-03 |
| JP2010518860A5 true JP2010518860A5 (enExample) | 2011-04-07 |
Family
ID=39710712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550979A Pending JP2010518860A (ja) | 2007-02-20 | 2008-02-20 | Ｌｙｎキナーゼの活性化剤の同定方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100152215A1 (enExample) |
| EP (1) | EP2120581A4 (enExample) |
| JP (1) | JP2010518860A (enExample) |
| KR (1) | KR20100014480A (enExample) |
| CN (1) | CN101686686A (enExample) |
| AU (1) | AU2008218765A1 (enExample) |
| BR (1) | BRPI0807928A2 (enExample) |
| CA (1) | CA2678813A1 (enExample) |
| IL (1) | IL200429A0 (enExample) |
| MX (1) | MX2009008874A (enExample) |
| NZ (1) | NZ579227A (enExample) |
| WO (1) | WO2008103692A2 (enExample) |
| ZA (1) | ZA200905776B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB201010196D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| CN102507707B (zh) * | 2011-10-12 | 2015-10-21 | 山东大学 | 一种检测龈沟液中蛋白裂解酶含量的方法 |
| CN104271140B (zh) * | 2011-12-12 | 2016-11-23 | 梅里奥尔医药I公司 | I型和ii型糖尿病的治疗 |
| US9827222B2 (en) * | 2013-07-01 | 2017-11-28 | Emory University | Treating or preventing nephrogenic diabetes insipidus |
| WO2015099094A1 (ja) | 2013-12-27 | 2015-07-02 | 国立大学法人東京医科歯科大学 | アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法 |
| AU2019223911A1 (en) * | 2018-02-21 | 2020-07-23 | Melior Pharmaceuticals I, Inc. | Treatment of liver diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3922345A (en) * | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| US4080454A (en) * | 1976-07-16 | 1978-03-21 | Pfizer Inc. | 5-M-Tolyloxyuracil, anti-ulcer agent |
| US4612376A (en) * | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
| US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| SE9203753D0 (sv) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| US6900304B2 (en) * | 1996-01-31 | 2005-05-31 | The Regents Of The University Of California | Emission ratiometric indicators of phosphorylation |
| US20020019346A1 (en) * | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
| GB0104422D0 (en) * | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| EP1618094B1 (en) * | 2003-04-30 | 2007-09-05 | The Institutes for Pharmaceutical Discovery, LLC | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
| EP1541694A1 (en) * | 2003-12-12 | 2005-06-15 | Sirenade Pharmaceuticals AG | Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase |
| US20060035302A1 (en) * | 2004-06-21 | 2006-02-16 | Applera Corporation | Kinase substrates with multiple phosphorylation sites |
| JP2008521900A (ja) * | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| ITUD20050112A1 (it) * | 2005-07-01 | 2007-01-02 | Gaetano Azzolina | Dispositivo di assistenza cardiocircolatoria |
| TWI273177B (en) * | 2005-07-08 | 2007-02-11 | Ama Precision Inc | Fan apparatus with adapting device |
| WO2007016975A1 (en) * | 2005-07-29 | 2007-02-15 | F. Hoffmann-La Roche Ag | Kinase and phosphatase assays based on fret |
| NZ565955A (en) * | 2005-08-22 | 2011-08-26 | Melior Pharmaceuticals I Inc | Methods and formulations for modulating lyn kinase activity and treating related disorders |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
-
2008
- 2008-02-20 AU AU2008218765A patent/AU2008218765A1/en not_active Abandoned
- 2008-02-20 NZ NZ579227A patent/NZ579227A/xx not_active IP Right Cessation
- 2008-02-20 BR BRPI0807928-5A patent/BRPI0807928A2/pt not_active IP Right Cessation
- 2008-02-20 KR KR1020097019560A patent/KR20100014480A/ko not_active Withdrawn
- 2008-02-20 EP EP08730208A patent/EP2120581A4/en not_active Withdrawn
- 2008-02-20 CN CN200880012768A patent/CN101686686A/zh active Pending
- 2008-02-20 US US12/527,801 patent/US20100152215A1/en not_active Abandoned
- 2008-02-20 JP JP2009550979A patent/JP2010518860A/ja active Pending
- 2008-02-20 MX MX2009008874A patent/MX2009008874A/es not_active Application Discontinuation
- 2008-02-20 CA CA002678813A patent/CA2678813A1/en not_active Abandoned
- 2008-02-20 WO PCT/US2008/054361 patent/WO2008103692A2/en not_active Ceased
-
2009
- 2009-08-17 IL IL200429A patent/IL200429A0/en unknown
- 2009-08-19 ZA ZA200905776A patent/ZA200905776B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Faridoon et al. | An update on the discovery and development of reversible covalent inhibitors | |
| JP2010518860A5 (enExample) | ||
| AU2013366513B2 (en) | Novel benzimidazole derivatives as kinase inhibitors | |
| Mahapatra et al. | New solid state forms of the anti-HIV drug efavirenz. Conformational flexibility and high Z′ issues | |
| MY150289A (en) | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | |
| TR201807023T4 (tr) | Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. | |
| JP2013530964A5 (enExample) | ||
| RU2008108898A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| JP2007517807A5 (enExample) | ||
| CA2616451C (en) | Substituted benzyl derivatives as gsk-3 inhibitors | |
| KR20100101056A (ko) | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 | |
| CN107207489A (zh) | 作为nadph氧化酶抑制剂的酰氨基噻二唑衍生物 | |
| CA2650326A1 (en) | N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors | |
| JP2013513596A5 (enExample) | ||
| RU2014134909A (ru) | Азагетероциклические соединения | |
| JP2012524076A (ja) | プロテインキナーゼｃｋ２活性に関連する障害の治療方法 | |
| HUP0202399A2 (hu) | Dopamin D3 receptor ligandumok alkalmazása veseelégtelenség kezelésére szolgáló gyógyszerek előállítására | |
| CN101505755B (zh) | 抗癌药耐性克服剂 | |
| JP2005538944A5 (enExample) | ||
| JP2009541387A5 (enExample) | ||
| CA3245082A1 (en) | PCNA INHIBITORS AND RELATED USES | |
| EP4126815A1 (en) | Stable heavy isotopes in amide functional groups and uses thereof | |
| Volkova et al. | The solubility of ethionamide and structural analogues in buffer solutions, octanol and hexane at several temperatures | |
| CN114206868A (zh) | 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物 | |
| JP7652791B2 (ja) | α－シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物 |